SpliSense is dedicated to the development of mutation specific therapies for cystic fibrosis based on splicing modulation using antisense oligonucleotide (ASO) technology to treat the underlying root cause of the disease and not to treat the symptoms. The scientific founders of the company, Prof. Batsheva Kerem and Prof. Eitan Kerem from the Hebrew University of Jerusalem have between them over 60 years of experience and expertise in the field of Cystic Fibrosis with strong molecular and clinical understanding of the disease, as well as playing pivotal roles in designing and conducting clinical trials in CF
February 2017
Hardware, Software

Register Pro to view more


$25 per month

Sign up to keep browsing

You reached your pageview limit

  • Save profiles to your list
  • Basic search functionality
  • Browse our leading AI database

Select a Table to Export